or Try an Advanced Search...

    Metastatic Colorectal Cancer Stocks List

    Symbol Grade Name % Change
    CRDF B Cardiff Oncology, Inc. -21.43
    NKTR A Nektar Therapeutics -6.89
    REGN C Regeneron Pharmaceuticals, Inc. 1.95
    View As Page of Charts
    Related Industries: Biotechnology Diagnostics & Research
    Related Stock Lists: Colorectal Cancer Biopharmaceutical Biotechnology Clinical Development Drugs Immunology Medicine Nektar Therapeutics Pain Pharmaceutical Acute Myeloid Leukemia Acute Pain Adenosine Advanced Solid Tumors Aminoglycoside Angiogenesis Anti Infectives Antibiotics Antibodies Antineoplastic Drugs

    Related ETFs - A few ETFs which own one or more of the above listed Metastatic Colorectal Cancer stocks.

    Symbol Grade Name Weight
    IBBQ C Invesco Nasdaq Biotechnology ETF 8.16
    IBB C iShares Nasdaq Biotechnology Index Fund 8.14
    BBH C Market Vectors Biotech ETF 7.72
    BIB C ProShares Ultra Nasdaq Biotechnology 5.92
    PJP B PowerShares Dynamic Pharmaceuticals 5.57
    View all Metastatic Colorectal Cancer ETFs...
    Compare ETFs
    Compare IBB to BBH Compare IBB to BIB Compare IBBQ to BIB

        Metastatic Colorectal Cancer Stocks Recent News

        Date Stock Title
        May 3 REGN Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2024 Earnings Call Transcript
        May 3 REGN Regeneron Pharmaceuticals First Quarter 2024 Earnings: Misses Expectations
        May 3 REGN Regeneron Pharmaceuticals Inc (REGN) Q1 2024 Earnings Call Transcript Highlights: Key Financial ...
        May 3 CRDF Cardiff Oncology, Inc. (CRDF) Q1 2023 Earnings Call Transcript
        May 3 REGN Decoding Regeneron Pharmaceuticals Inc (REGN): A Strategic SWOT Insight
        May 2 NKTR Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets
        May 2 CRDF Cardiff Oncology GAAP EPS of -$0.22 beats by $0.03, revenue of $0.2M beats by $0.14M
        May 2 CRDF Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update
        May 2 REGN Regeneron Pharmaceuticals, Inc. (REGN) Q1 2024 Earnings Call Transcript
        May 2 REGN Regeneron (REGN) Q1 Earnings, Sales Miss on Lower Eylea Sales
        May 2 REGN Regeneron (REGN) Reports Q1 Earnings: What Key Metrics Have to Say
        May 2 REGN Regeneron Pharmaceuticals Inc (REGN) Q1 2024 Earnings: Challenges and Opportunities Amidst ...
        May 2 REGN Regeneron Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call Presentation
        May 2 REGN Is Weakness In Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
        May 2 REGN Regeneron falls after Q1 miss; announces $3B share buybacks
        May 2 REGN 3 Biotech Stocks to Buy and Hold Through 2030 and Beyond
        May 2 REGN Regeneron Earnings Miss; Biotech Giant's Stock Falls
        May 2 REGN Regeneron Pharmaceuticals misses top-line and bottom-line estimates; updates FY24 outlook
        May 2 REGN Regeneron Reports First Quarter 2024 Financial and Operating Results
        May 1 CRDF Cardiff Oncology Q1 2024 Earnings Preview
        Related Industries: Biotechnology Diagnostics & Research
        Related Stock Lists: Colorectal Cancer Biopharmaceutical Biotechnology Clinical Development Drugs Immunology Medicine Nektar Therapeutics Pain Pharmaceutical Acute Myeloid Leukemia Acute Pain Adenosine Advanced Solid Tumors Aminoglycoside Angiogenesis Anti Infectives Antibiotics Antibodies Antineoplastic Drugs
        Metastatic Colorectal Cancer

        Metastatic colorectal cancer is a type of cancer that has spread from the colon or rectum to other parts of the body, such as the liver, lungs, or other organs. It is the most advanced stage of colorectal cancer and is often difficult to treat. Symptoms of metastatic colorectal cancer can include abdominal pain, fatigue, weight loss, and changes in bowel habits. Treatment options may include chemotherapy, radiation therapy, and/or surgery.

        Browse All Tags